Business · 29/07/2024Updated: 10/17/2026 · 1 min read

FDA Renews Pulmonary-Allergy Drugs Advisory Committee for 2 Years

The FDA has renewed the Pulmonary-Allergy Drugs Advisory Committee for an additional 2 years, with the new charter set to expire on May 30, 2026, following a determination by the Commissioner of Food and Drugs that it is in the public interest.